Drugs / Anitocabtagene Autoleucel
Anitocabtagene Autoleucel
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06626919 | Apr 2025 → Mar 2027 expected | myasthenia gravis, myopathy, neuromuscular disease | Arcellx, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT04155749 | Dec 2019 → Oct 2024 overdue | refractory plasma cell neoplasm | Kite, A Gilead Company | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07045909 | Jun 2025 → Mar 2028 expected | plasma cell myeloma | PETHEMA Foundation | Recruiting | No outcome recorded |
| Phase 2 | NCT05396885 | Jul 2022 → Dec 2026 expected | plasma cell myeloma | Kite, A Gilead Company | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06413498 | Aug 2024 → Jul 2028 expected | plasma cell myeloma | Kite, A Gilead Company | Active not recruiting | No outcome recorded |
Press releases naming this drug 10 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-28 | Kite, A Gilead Company | Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel kitepharma.com ↗ |
| 2026-04-28 | Gilead Sciences | Gilead Sciences Completes Acquisition of Arcellx Ahead of Potential Commercial Launch of Anito-cel gilead.com ↗ |
| 2026-02-23 | Kite, A Gilead Company | Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel kitepharma.com ↗ |
| 2026-02-23 | Gilead Sciences | Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel gilead.com ↗ |
| 2025-12-06 | Kite, A Gilead Company | Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma kitepharma.com ↗ |
| 2025-12-06 | Gilead Sciences | Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma gilead.com ↗ |
| 2024-05-09 | Kite, A Gilead Company | Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program kitepharma.com ↗ |
| 2024-05-09 | Gilead Sciences | Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program gilead.com ↗ |
| 2023-01-30 | Kite, A Gilead Company | Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma kitepharma.com ↗ |
| 2022-12-09 | Kite, A Gilead Company | Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma kitepharma.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anitocabtagene-autoleucel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05396885 ↗ |
| Known as | anito-cel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06626919 ↗ |
| Known as | Anitocabtagen autoleucel | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314723 ↗ |
| Known as | CART-ddBCMA | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314723 ↗ |
| Modality | Cell therapy | “Anitocabtagene-autoleucel is a BCMA-directed CAR-T cell therapy.” NCT05396885 ↗ |
| Route | Intravenous | “Single dose of 115±10 x 10e-6 CAR+ anitocabtagene-autoleucel cells infused intravenously” NCT05396885 ↗ |